The authorities of India banned the export of antiviral Remdesivir drug and its active pharmaceutical ingredients due to the growth of demand for the drug amid a new coronavirus outbreak as Reuters reported.
The growth of demand for Remdesivir led to its severe shortage in many regions of the country.
On Sunday, the number of newly infected people increased up to 152,879 and it is the sixth record of incidence growth in seven days. The relatives of the patients made a kilometer-long line near the large hospital in Gujarat state to buy Remdesivir.
India known as the world supplier of drugs has already stopped the export of the vaccines against coronavirus. The Health Ministry asked the producers to increase the supply of Remdesivir for the inner needs of the country.
Seven Indian companies received licenses for issuance of the drug from the American Gilead Sciences producer with an installed capacity of about 3.9 million units per month for local use and export to over 100 countries. These companies are Cipla, Dr. Reddy’s Laboratories, Hetero Labs, Jubilant Life Sciences, Biocon’s Syngene, Zydus Cadila Healthcare and the Indian unit of Mylan.
Earlier, the World Health Organization (WHO) issued a conditional recommendation against the use of Remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that Remdesivir improves survival and other outcomes in these patients.